Wilson Tang, M.D., Zeneng Wang, Ph.D., Bruce S
In a 2023 animal and laboratory study, researchers suggested that GLP-1 medications could have the following benefits for people with UC: lowering the levels of proinflammatory mediators chemicals that cause inflammation preventing certain important proteins and pathways in the body from becoming overactive, which can contribute to UC repairing damage to the inner lining of the intestines improving the balance of good bacteria in the gut The researchers suggested that GLP-1 medications may be a promising future treatment for UC
In this study, the antibacterial properties of synthetic cholic acid derivatives ceragenins CSA-13, CSA-44 and CSA-131, custom-synthesized peptides human cathelicidin LL-37 peptide, synthetic WLBU2 peptide, and antimicrobial VFR12 peptide of human thrombin origin were evaluated to determine their potentials as therapeutic agents for bloodstream infections
Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice
Diabetologia 51, 15521553
These actions are likely due to the potential of BPC-157 to simulate vasodilatation and angiogenesis (new blood vessel formation) due to its action on peptidergic growth factors such as endothelial growth factor, Consequently, the peptide has demonstrated significant protective effects against gastric mucosal injury in rat models
:format(webp))
